Evixapodlin

• CAT Number: I027165
• CAS Number: 2374856-75-2
• Molecular Formula: C34H36Cl2N8O4
• Molecular Weight: 691.61
• Purity: ≥95%
• Synonyms: Evixapodlin
• Target: Anti-infection
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
• IUPAC Name: (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one
• InChI: InChI=1S/C34H36Cl2N8O4/c1-47-33-27(15-37-13-19-9-11-29(45)41-19)39-17-25(43-33)23-7-3-5-21(31(23)35)22-6-4-8-24(32(22)36)26-18-40-28(34(44-26)48-2)16-38-14-20-10-12-30(46)42-20/h3-8,17-20,37-38H,9-16H2,1-2H3,(H,41,45)(H,42,46)/t19-,20-/m0/s1
• InChIKey: OIIOPWHTJZYKIL-PMACEKPBSA-N
• SMILES: O=C1CC[C@@]([H])(CNCC2=NC=C(C3=CC=CC(C4=C(Cl)C(C5=NC(OC)=C(CNC[C@@]6([H])NC(CC6)=O)N=C5)=CC=C4)=C3Cl)N=C2OC)N1

Evixapodlin (Cat.No:I027165) is an experimental small molecule targeting the protein phosphatase 1 (PP1) to modulate immune responses. It is under investigation for its potential in treating autoimmune diseases and inflammatory disorders by selectively inhibiting PP1 activity. By modulating T-cell activation and cytokine production, Evixapodlin shows promise in reducing inflammation and autoimmune symptoms. Its precise mechanism of action offers a novel approach for therapeutic intervention in immune-related conditions, with ongoing studies evaluating its efficacy and safety profiles.